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9791-Year Results From the
NOTION Randomized
Clinical Trial
No News Is Good News?The NOTION (Nordic Aortic Valve Intervention) trial
compared transcatheter aortic valve replacement
(TAVR) versus surgical aortic valve replacement
(SAVR) in predominantly low-risk patients (1). Avail-
able evidence is consistent in suggesting that TAVR is
associated with a better immediate outcome, given
the less invasive nature of the procedure. However,
the less favorable immediate outcome reported
with SAVR is offset by improved survival, which is
the primary therapeutic goal for patients at low- and
intermediate-risk.
As partly recognized by Thyregod et al. (1), there
are several study limitations to acknowledge:
 Patients with signiﬁcant concomitant coronary
disease were not recruited, so that nearly 90% of
patients were excluded at enrollment. In other
words, it is not for “all-comers,” as the title says.
 Hospital costs are higher for TAVR than SAVR pro-
cedures, and the hypothesis tested in the study would
result in an unsustainable healthcare expenditure.
 The “modern TAVR” is compared with the “ancient
SAVR.” However, it should be taken into consider-
ation that, at present, SAVR can be performed using
different approaches (e.g., minimally invasive sur-
gery, sutureless bioprostheses) that may compete
well with current interventional techniques.
 The rate of post-operative cardiogenic shock and
major/life-threatening bleeding in this low-risk
SAVR population seem unusually high (10.6% and
>20%).
 The high rate of post-operative pacemaker im-
plantation in the TAVR group (34.1%) seems to be
correlated with the prosthetic device used rather
than with TAVR per se. This complication deserves
further discussion, given the well-known associa-
tion between pacemaker stimulation and ventric-
ular deterioration.
 At 1-year follow-up, TAVR patients had more dys-
pnea compared with SAVR patients, likely due
to paraprosthetic regurgitation. This has been
frequently described as a complication occurring
with current-generation TAVR devices and has been
associated with increased mortality. However, the
mortality rate after TAVR in the NOTION trial is 1 of
the lowest ever reported, and the short follow-up
period can account for this positive ﬁnding.*Giuseppe Santarpino, MD
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More or Less?With interest we read the paper by Thyregod et al. (1)
on transcatheter aortic valve replacement (TAVR)
versus surgical aortic valve replacement (SAVR) in
patients with severe aortic valve stenosis. TAVR has
been considered an acceptable treatment option for
patients with inoperable severe aortic valve stenosis
or at high risk for surgery (2). The NOTION (Nordic
Aortic Valve Intervention Trial) study was the ﬁrst
randomized trial comparing TAVR with SAVR in an
all-comers patient population with severe symptom-
atic aortic valve stenosis regardless of their predicted
morality score. It was a multicenter, randomized,
nonblinded, superiority trial.
No signiﬁcant differences were found regarding
death from any cause, stroke, or myocardial infarc-
tion; cardiovascular mortality; or prosthesis re-
intervention after 1 year. Power calculations in the
trial were far too weak to detect a small (z3%)
absolute difference in primary outcome between
groups. Need for permanent pacemaker implantation
(38.0% vs. 2.4%; p < 0.001), New York Heart Associ-
ation functional class II at 1 year (29.5% vs. 15.0%;
p ¼ 0.01), and moderate-to-severe regurgitation at
1 year (15.7% vs. 0.9%; p < 0.001) were all better in
the SAVR group. Bleeding, acute kidney injury,
cardiogenic shock, new-onset atrial ﬁbrillation, and
duration of indexed hospitalization were better in the
TAVR group, although they did not corroborate to a
worse overall 1-year outcome or a difference in the
